Showing results (151-160 of 187) with videos related to

Sort By:
Pageof 19
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 14, 2025
Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter studyAtsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective AnalysisTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Journal of Gastroenterology|August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine|February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical PracticeHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 12, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinibIlario Giovanni Rapposelli, Toshifumi Tada, Shigeo Shimose, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter AnalysisTomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2025
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B StudyRui Huang, Ai-Thien Do, Hidenori Toyoda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Pageof 19